7297DMT26Poster-Disease-modifying TherapyElizabeth A Douglas Archives - 2021 CMSC Annual Meeting

2021 CMSC Annual Meeting

Tag: 7297DMT26Poster-Disease-modifying TherapyElizabeth A Douglas

Poster-Disease-modifying Therapy

October 25, 2021

Acapella: Real-World Experience with Ocrelizumab: An Observational Study Evaluating Safety in Patients with Relapsing and Progressive MS, Year Four Data

Background: Ocrelizumab (OCR) is a humanized, monoclonal antibody targeting CD20+ B cells and is approved for treatment of relapsing...

Read More →

MAILING ADDRESS

3 University Plaza Drive, Ste 116
Hackensack, NJ 07601

CONTACT US

(201) 487-1050
info@mscare.org

FOLLOW US

© 2021 CMSC